Cresset Asset Management, LLC Biomarin Pharmaceutical Inc Transaction History

Cresset Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $5,135 - $6,363	-69 Reduced 2.6%	2,583 $212,000
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $159,071 - $187,902	-1,898 Reduced 41.71%	2,652 $231,000
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $71,799 - $92,796	942 Added 26.11%	4,550 $438,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $8,592 - $9,542	101 Added 2.88%	3,608 $319,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $303,986 - $351,752	3,507 New	3,507 $303,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $222,542 - $277,699	-2,996 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $214,873 - $274,044	2,996 New	2,996 $265,000
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $16,712 - $19,531	-208 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $6,315 - $7,396	75 Added 56.39%	208 $18,000
Q4 2018 May 21, 2019	BUY	$80.14 - $106.07 $10,658 - $14,107	133 New	133 $11,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.